The US Food and Drug Administration (FDA) has just announced the approval of Cyltezo (adalimumab-adbm) as an interchangeable biosimilar to Humira.
According to the country's regulations, a product of this type is a biosimilar that meets the additional requirements established by law that allows the FDA to assign this name, and the substitution of the original is possible without the intervention of the health professional. who prescribed the reference product.

READ MORE